Maze Therapeutics (MAZE) EBITDA Margin (2024 - 2026)

Maze Therapeutics (MAZE) reported EBITDA Margin of 132.76% for Q1 2026, down 781.11% sequentially from 19.49% in Q4 2024.

Maze Therapeutics (MAZE) EBITDA Margin (2024 - 2026) Analysis & Trends

Maze Therapeutics (MAZE) has 2 years of EBITDA Margin data on file, last reported at 132.76% in Q1 2026.

For the quarter ending Q1 2026, EBITDA Margin changed N/A year-over-year to 132.76%; the trailing twelve-month figure through Mar 2026 stood at 670.26% (down 63307.0% YoY), and the FY2024 full-year result was 383.91%, changed N/A from the prior year.
EBITDA Margin retreated to 132.76% in Q1 2026, from 19.49% in the prior quarter.
In the past five years, EBITDA Margin ranged from a high of 930.37% in Q2 2024 to a low of 969.16% in Q3 2024.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	16.51%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	17.83%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Maze Therapeutics	1.49 Bn	1.49 Bn	18.21 Mn	-132.77%

Historic Data

Download Data

Date	Value
Mar 31, 2026	-132.77%
Dec 31, 2024	19.49%
Sep 30, 2024	-969.16%
Jun 30, 2024	930.37%